Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2339344 | 0.89 | TSHR (0.49) | LCKFYNKDM4EMAPK1KMT2A | |
| SCHEMBL12245587 | 0.86 | LCK (0.55) | LCKFYNKDM4EMAPK1KMT2A | |
| SCHEMBL14914576 | 0.83 | TSHR (0.47) | LCKFYNKDM4EMAPK1KMT2A | |
| SCHEMBL31412877 | 0.82 | TSHR (0.43) | LCKFYNKDM4EMAPK1KMT2A | |
| SCHEMBL30575711 | 0.82 | TSHR (0.43) | LCKFYNKDM4EMAPK1KMT2A | |
| SCHEMBL7279292 | 0.80 | LCK (0.56) | LCKFYNKDM4EMAPK1KMT2A | |
| SCHEMBL14915520 | 0.77 | SMN1; SMN2 (0.51) | KDM4EKMT2AMEN1GFERMAPT | |
| SCHEMBL1417516 | 0.77 | LCK (0.72) | LCKFYNKDM4EMAPK1KMT2A | |
| SCHEMBL30415497 | 0.77 | LCK (0.72) | LCKFYNKDM4EMAPK1KMT2A | |
| SCHEMBL7316761 | 0.74 | HTT (0.55) | LCKFYNKDM4EMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308610-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-06-04 | — | — | US | disclosed |
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-04-12 | — | — | US | disclosed |
| US-9856220-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-01-02 | — | — | US | disclosed |
| EP-2780324-B1 | HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-05-17 | — | — | EP | disclosed |
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. | 2016-11-03 | — | — | US | disclosed |
| CN-104203919-A | eterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10A | ABBVIE DEUTSCHLAND | 2014-12-10 | — | — | CN | disclosed |
| EP-2780324-A1 | HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | Abbvie Deutschland GmbH & Co. KG (DE) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013068489-A1 | HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT GMBH & CO. KG (DE) | 2013-05-16 | — | — | WO | disclosed |
| US-20130116229-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE3A, PDE5A, PDE3B | LCK 2981/4885FYN 712/4885KDM4E 2209/4885 |
| US-10308610-B2 | Inhibitor compounds of phosphodiesterase type 10A | PDE3A, PDE5A, PDE3B | LCK 2690/4885FYN 671/4885KDM4E 2227/4885 |
| US-20130116229-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE7A, PDE5A, PDE2A | LCK 3989/4885FYN 2515/4885KDM4E 1376/4885 |
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE3A, PDE5A, PDE3B | LCK 2984/4885FYN 717/4885KDM4E 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.